M. Bono

发表

BRCA1/2 pathogenic variants in triple-negative versus luminal-like breast cancers: genotype–phenotype correlation in a cohort of 531 patients

A. Russo, V. Bazan, V. Caló, 2020, Therapeutic advances in medical oncology.

Hereditary Breast and Ovarian Cancer in Families from Southern Italy (Sicily)—Prevalence and Geographic Distribution of Pathogenic Variants in BRCA1/2 Genes

A. Russo, V. Bazan, V. Caló, 2020, Cancers.

Body Mass Index (BMI) is not a cancer risk factor for BRCA1/2 carriers: a Systematic Review and Meta-analysis of case-control studies

A. Russo, F. Fulfaro, V. Bazan, 2021 .

Programmed Death Ligand 1 (PD-L1) as a Predictive Biomarker for Pembrolizumab Therapy in Patients with Advanced Non-Small-Cell Lung Cancer (NSCLC)

A. Russo, S. Vieni, V. Bazan, 2019, Advances in Therapy.

Impact of deleterious variants in other genes beyond BRCA1/2 detected in breast/ovarian and pancreatic cancer patients by NGS-based multi-gene panel testing: looking over the hedge

F. Guadagni, V. Bazan, V. Caló, 2021, ESMO open.

BRCA1/2 variants of unknown significance in hereditary breast and ovarian cancer (HBOC) syndrome: looking for the hidden meaning.

S. Vieni, V. Bazan, D. Fanale, 2022, Critical reviews in oncology/hematology.

Prevalence and Spectrum of Germline BRCA1 and BRCA2 Variants of Uncertain Significance in Breast/Ovarian Cancer: Mysterious Signals From the Genome

A. Russo, V. Bazan, V. Caló, 2021, Frontiers in Oncology.

Detection of Germline Mutations in a Cohort of 139 Patients with Bilateral Breast Cancer by Multi-Gene Panel Testing: Impact of Pathogenic Variants in Other Genes beyond BRCA1/2

A. Russo, V. Bazan, V. Caló, 2020, Cancers.

Non-Small Cell Lung Cancer Harboring Concurrent EGFR Genomic Alterations: A Systematic Review and Critical Appraisal of the Double Dilemma

A. Russo, V. Bazan, V. Caló, 2021 .

Exploring the Dynamic Crosstalk between the Immune System and Genetics in Gastrointestinal Stromal Tumors

V. Bazan, V. Gristina, A. Galvano, 2022, Cancers.

Cardiovascular Risk in Essential Thrombocythemia and Polycythemia Vera: Thrombotic Risk and Survival

A. Russo, S. Raso, F. Di Piazza, 2020, Mediterranean journal of hematology and infectious diseases.

A “Lymphocyte MicroRNA Signature” as Predictive Biomarker of Immunotherapy Response and Plasma PD-1/PD-L1 Expression Levels in Patients with Metastatic Renal Cell Carcinoma: Pointing towards Epigenetic Reprogramming

A. Russo, V. Bazan, J. Iovanna, 2020, Cancers.

Prognostic role of soluble PD-1 and BTN2A1 in overweight melanoma patients treated with nivolumab or pembrolizumab: finding the missing links in the symbiotic immune-metabolic interplay

V. Bazan, G. Rinaldi, D. Fanale, 2023, Therapeutic advances in medical oncology.

Moving the Target on the Optimal Adjuvant Strategy for Resected Pancreatic Cancers: A Systematic Review with Meta-Analysis

A. Russo, F. Fulfaro, V. Bazan, 2020, Cancers.

Clinical Potential of Circulating Cell-Free DNA (cfDNA) for Longitudinally Monitoring Clinical Outcomes in the First-Line Setting of Non-Small-Cell Lung Cancer (NSCLC): A Real-World Prospective Study

V. Bazan, E. Francini, L. Castellana, 2022, Cancers.

Cardiovascular Risk in Polycythemia Vera: Thrombotic Risk and Survival: Can Cytoreductive Therapy Be Useful in Patients with Low-Risk Polycythemia Vera with Cardiovascular Risk Factors?

A. Russo, S. Raso, F. Di Piazza, 2020, Oncology Research and Treatment.

Immuno-targeted combinations in oncogene-addicted non-small cell lung cancer

G. Pantuso, F. Passiglia, L. Castellana, 2018, Translational cancer research.

Not all KIT 557/558 codons mutations have the same prognostic influence on recurrence-free survival: breaking the exon 11 mutations in gastrointestinal stromal tumors (GISTs)

A. Russo, V. Bazan, G. Pantuso, 2021, Therapeutic advances in medical oncology.

Can the tumor-agnostic evaluation of MSI/MMR status be the common denominator for the immunotherapy treatment of patients with several solid tumors?

V. Bazan, G. Pantuso, D. Fanale, 2022, Critical reviews in oncology/hematology.

Roles of Tumor-Rducated Platelets (TEPs) in the biology of Non-Small Cell Lung Cancer (NSCLC): A systematic review. “Re-discovering the neglected biosources of the liquid biopsy family”

V. Bazan, V. Gristina, A. Galvano, 2024, The Journal of Liquid Biopsy.

Clinical relevance of exosome-derived microRNAs in Ovarian Cancer: looking for new tumor biological fingerprints.

G. Pantuso, D. Fanale, A. Russo, 2023, Critical reviews in oncology/hematology.

Polθ: emerging synthetic lethal partner in homologous recombination-deficient tumors.

V. Gristina, A. Galvano, L. Incorvaia, 2024, Cancer gene therapy.